Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial
Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara, Achim Berthele et autres
BACKGROUND: Antibodies to the aquaporin-4 (AQP4) water channel in neuromyelitis optica spectrum disorder (NMOSD) are reported to trigger the complement cascade, which is implicated in astrocyte damage and subsequent neuronal injury. The PREVENT study demonstrated that the terminal complement inhibitor eculizumab reduces …
gb, us, jp, de, es, kr, tr, ru, my, tw (code pays fourni par la source)
42 citations
Multiple Sclerosis and Related Disorders